Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.

Clicks: 187
ID: 275491
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #73 of 122 articles by views in Journal of medicinal chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
After identification of lead compound , 5-amino-1,4-oxazine BACE1 inhibitors were optimized in order to improve potency, brain penetration, and metabolic stability. Insertion of a methyl and a trifluoromethyl group at the 6-position of the 5-amino-1,4-oxazine led to (), an inhibitor with a p of 7.1, a very low P-glycoprotein efflux ratio, and excellent pharmacological profile, enabling high central nervous system penetration and exposure. Fur color changes observed with in efficacy studies in preclinical animal models triggered further optimization of the series. Herein, we describe the steps leading to the discovery of 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [6-((3,6)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide (, ), an inhibitor with superior BACE1/BACE2 selectivity and pharmacokinetics. reduced significantly Aβ levels in mice and rats in acute and chronic treatment regimens without any side effects and thus qualified for Alzheimer's disease prevention studies in the clinic.
Reference Key
machauer2021discoveryjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Machauer, Rainer;Lueoend, Rainer;Hurth, Konstanze;Veenstra, Siem J;Rueeger, Heinrich;Voegtle, Markus;Tintelnot-Blomley, Marina;Rondeau, Jean-Michel;Jacobson, Laura H;Laue, Grit;Beltz, Karen;Neumann, Ulf;
Journal Journal of medicinal chemistry
Year 2021
DOI
10.1021/acs.jmedchem.1c01300
URL
Keywords
X-ray crystallography Mycobacterium tuberculosis tuberculosis drug discovery cyp121

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.